April 28 (Reuters) - CRISPR Therapeutics AG:
* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS
* CRISPR THERAPEUTICS AG - CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2020, WERE $889.7 MILLION
* CRISPR THERAPEUTICS AG QTRLY TOTAL COLLABORATION REVENUE WAS $0.2 MILLION VERSUS $0.3 MILLION
* CRISPR THERAPEUTICS AG QTRLY BASIC LOSS PER SHARE $1.15)
* CRISPR THERAPEUTICS AG - ENROLLMENT ONGOING IN CLINICAL TRIALS OF CTX001 FOR PATIENTS WITH SEVERE HEMOGLOBINOPATHIES
* CRISPR THERAPEUTICS AG - ENROLLMENT ONGOING IN CLINICAL TRIAL OF CTX110, TARGETING CD19+ MALIGNANCIES Source text for Eikon: Further company coverage:
Our Standards:The Thomson Reuters Trust Principles.
